ClinicalTrials.gg
Drug

Zanzalintinib clinical trials

Also written XL092.

studies test it
50
open now
42
in phase 3
8
first study started
2017

How each study uses zanzalintinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the zanzalintinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Zanzalintinib
43
Multi-kinase Inhibitor XL092
5

Development codes

XL092
38

Studies by the year they started

48 studies that test it; most in 2026 (24); 2 more planned to start later

Studies that test zanzalintinib, by start year
YearStudies
20171
20191
20211
20221
20231
20245
202514
202624

Who runs them

Industry 17 · Other 33

Exelixis (13) · M.D. Anderson Cancer Center (5) · Washington University School of Medicine (4) · Merck Sharp & Dohme LLC (3) · UNC Lineberger Comprehensive Cancer Center (2) · Stuthi Perimbeti (1) · University of Texas Southwestern Medical Center (1) · Pedro Barata, MD, MSc (1)

Often tested with

Tested in the same studies.

Cabozantinib (1) · Tegavivint (1) · Cemiplimab (1) · C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 (1) · Cobimetinib (1) · Cibisatamab (1) · Docetaxel (1) · Ciforadenant (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 6, 1 in phase 3

Studies that test zanzalintinib, phase 3 first.

Studies

Open first, then newest update. How each study uses zanzalintinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 50

See all 50 studies that test zanzalintinib →

Given beside what is tested · 1 — zanzalintinib is usual care or a partner of the new treatment

Codes

What other systems call zanzalintinib · ClinicalTrials.gg INT017046

  • UNII (FDA) KC2JC2ZA04ZANZALINTINIBConfirmed FDA, Wikidata
  • Wikidata Q124353001zanzalintinibConfirmed FDA, Wikidata
  • NCI Thesaurus C161598ZanzalintinibOne source FDA
  • DrugBank DB17525One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.